[HTML][HTML] 34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1 …
S Banerjee, A Leary, JR Stewart, M Dewan… - ESMO Open, 2023 - esmoopen.com
Background Clinical outcomes for rare subtypes of relapsed gynaecological cancers (GC)
including ovarian clear cell carcinomas (CCC) and carcinosarcomas (CS) are poor with
limited treatment options. Preclinical data demonstrate GC with deleterious ARID1A
mutations (and thus ARID1A-protein loss) display increased sensitivity to ATR inhibition. In
the absence of ARID1A mutations, ATR inhibitor sensitivity can be enhanced by combination
with PARP inhibitors. ATARI is an academic, international, parallel cohort platform phase II …
including ovarian clear cell carcinomas (CCC) and carcinosarcomas (CS) are poor with
limited treatment options. Preclinical data demonstrate GC with deleterious ARID1A
mutations (and thus ARID1A-protein loss) display increased sensitivity to ATR inhibition. In
the absence of ARID1A mutations, ATR inhibitor sensitivity can be enhanced by combination
with PARP inhibitors. ATARI is an academic, international, parallel cohort platform phase II …